FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Apr 15, 2026
Kala Bio, Inc. (KALA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $27.0 million.
Revenue
$0
Net income
$-26.98M
+29.9% vs prior year
Operating cash flow (TTM)
$-19.86M
+23.3% vs year-ago TTM
Free cash flow
$-94.06M
-68.9% vs prior year
EPS
$-3.31
+67.4% vs prior year
Dividend per share
None
Shares outstanding
929.49M
+14305.4% vs prior year
Net cash
$18.93M
FY 2024
Operating margin
-2099.3%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KALA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Arlington, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1479419
- Former names
- KALA BIO, Inc. (until Nov 3, 2026); Kala Pharmaceuticals, Inc. (until Jun 23, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3.9M | $11.2M |
| Operating income | -$39.2M | -$41.0M | -$39.7M | -$81.7M | -$130.2M |
| Net income | -$27.0M | -$38.5M | -$42.2M | -$44.8M | -$142.6M |
| Diluted EPS | -$3.31 | -$10.15 | -$17.35 | -$29.48 | -$108.32 |
| Operating cash flow | -$32.0M | -$29.4M | -$27.9M | -$78.9M | -$108.2M |
| Total assets | $9.5M | $55.5M | $55.9M | $86.8M | $139.4M |
| Total liabilities | $2.5M | $43.2M | $48.4M | $67.8M | $122.6M |
| Stockholders' equity | $7.0M | $12.3M | $7.5M | $19.0M | $16.8M |
| Cash and investments | $7.6M | $51.2M | $50.9M | $70.5M | $92.1M |
| Total debt | — | $32.3M | $36.3M | $43.3M | $81.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 10, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 28, 2026 | Aug 27, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 23, 2026 | Jul 22, 2026 |
All 675 Kala Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.